Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).

标题
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 15_suppl, Pages 10543-10543
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2020-05-25
DOI
10.1200/jco.2020.38.15_suppl.10543

向作者/读者发起求助以获取更多资源

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started